With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.

Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.

Bristol-Myers Squibb will tap into the immuno-oncology expertise of the Parker Institute and Cancer Research Institute (CRI) in a bid to accelerate clinical…

Shares in Cerulean Pharma nosedived yesterday after the company agreed to sell off its anticancer assets at a bargain basement price and merge with Daré…

Astellas Pharma has struck a drug discovery deal worth up to $100 million per target with X-Chem.

Heptares Therapeutics has struck a pain drug R&D pact with Daiichi Sankyo.

Galapagos has turned to Pharnext to identify low-doses of approved drugs that boost the efficacy of its pipeline prospects.

Horizon Discovery has struck a deal to evaluate cell line optimization technology developed by Amplycell.

Bioversys has enlisted Aptuit to support its efforts to identify and validate novel targets and drugs against Gram-negative bacteria.